Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (NCT05263934)
A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy
🩺 Plain-English Summary (8th-Grade Level)
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (63 Sites)
Showing the first 25 of 63 sites.
- GSK Investigational Site — Denver, Colorado
- GSK Investigational Site — Gainesville, Florida
- GSK Investigational Site — Rochester, Minnesota
- GSK Investigational Site — New York, New York
- GSK Investigational Site — Charlotte, North Carolina
- GSK Investigational Site — Pittsburgh, Pennsylvania
- GSK Investigational Site — La Plata,
- GSK Investigational Site — San Miguel de Tucumán,
- GSK Investigational Site — Graz,
- GSK Investigational Site — Santo André,
- GSK Investigational Site — São Paulo,
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Beijing,
- GSK Investigational Site — Guangzhou,
- GSK Investigational Site — Hefei,
- GSK Investigational Site — Nanjing,
- GSK Investigational Site — Qingdao,
- GSK Investigational Site — Shanghai,
- GSK Investigational Site — Shenzhen,
- GSK Investigational Site — Wenzhou,
- GSK Investigational Site — La Roche-sur-Yon,
- GSK Investigational Site — Nantes,
- GSK Investigational Site — Paris,
- GSK Investigational Site — Freiburg im Breisgau,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Eosinophilic Granulomatosis With Polyangiitis
Explore by condition: All Eosinophilic Granulomatosis With Polyangiitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.